Plasma lipids and stroke

Journal of Cardiovascular Risk

Volumn 6, Issue 4, 1999, Pages 217-221

  Gorelick, Philip B ^a   Mazzone, Theodore ^b  

^a Center for Stroke Research   (United States)

^b RUSH MEDICAL COLLEGE   (United States)

Author keywords

Cholesterol; Hyperlipidemia; Lipids; Stroke

Indexed keywords

APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; TRIACYLGLYCEROL; LIPID;

CELL INTERACTION; HUMAN; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STROKE; ASYMPTOMATIC DISEASE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; CLINICAL RESEARCH;

EID: 84908700150     PISSN: 13506277     EISSN: None     Source Type: Journal    
DOI: 10.1177/204748739900600405     Document Type: Review

References (51)

1. The state of world health. In: The world health report 1997: conquering suffering and enriching humanity. France: World Health Organization; 1997. p. 44.
2. Stroke (brain attack). In: 1997 Heart and stroke statistical update. United States: American Heart Association; 1996. p. 13.
3. Gorelick PB. Stroke prevention: windows of opportunity and failed expectations? A discussion of modifiable cardiovascular risk factors and a prevention proposal. Neuroepidemiology 1997; 16:163-173.
4. Sacco RL, Benjamin EJ, Broderick JP, Dyken M, Easton DJ, Feinberg WM, et al. Risk factors. Stroke 1997; 28:1507-1517.
5. Gorelick PB, Schneck M, Berglund LF, Feinberg W, Goldstone J. Status of lipids as a risk factor for stroke. Neuroepidemiology 1997; 16:107-115. A good overview of the epidemiology of lipids in relation to stroke risk. The review includes treatment recommendations for stroke or stroke-prone patients with elevated blood levels of lipids.
6. Wissler RW. New insights into the pathogenesis of atherosclerosis as revealed by PDAY. Atherosclerosis 1994; 108:S3-S20.
7. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. Atheroscler Thromb Vasc Biol 1995; 15:1512-1531.
8. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362:801-809. A classic-type review of the pathogenesis of atherosclerosis. The role of blood lipids is emphasized.
9. Kruth HS. The fate of lipoprotein cholesterol entering the arterial wall. Curr Opin Lipidol 1997; 8:246-252.
10. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem 1997; 272:20963-20966.
11. Levine GN, Keaney JF, Vita JA. Cholesterol reduction in cardiovascular disease. N Engl J Med 1995; 332:512-521.
12. WHO/MNH Task Force on Stroke and Other Cerebrovascular Disorders (1989). Recommendations on stroke prevention, diagnosis and therapy. Stroke 1989; 20: 1407-1431.
13. Atkins D, Psaty BM, Koepsell TD, Longstreth WT Jr, Larson EB. Cholesterol reduction and the risk for stroke in men. A meta-analysis of randomized, controlled trials. Ann Intern Med 1993; 119:136-145.
14. Byington RP, Jukema JW, Salonen JT, Pitt B, Bruschke AV, Hoen H, et al. Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Program. Circulation 1995; 92:2419-2425.
15. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit. A new look at old data. Circulation 1995; 91:2274-2282. A good overview of the safety and efficacy of lipid lowering strategies. Statin agents are emphasized.
16. Benfante R, Yano K, Hwang L-J, Curb JD, Kagan A, Ross W. Elevated serum cholesterol is a risk factor for both coronary heart disease and thromboembolic stroke in Hawaiian Japanese men. Implications of shared risk. Stroke 1994; 25:814-820.
17. Hachinski V, Graffagnino C, Beaudry M, Bernier G, Buck C, Donner A, et al. Lipids and stroke. A paradox resolved. Arch Neurol 1996; 53:303-308.
18. Mack WJ, Selzer RH, Hodis HN, Erickson JK, Lir C-R, Liu C-H, et al. One-year reduction and longitudinal analysis of carotid intima-media thickness associated with colestipol/niacin therapy. Stroke 1993; 24:1779-1783.
19. Crouse JR, Byington RP, Bond MG, Espeland MA, Craven TE, Sprinkle JW, et al. Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II). Am J Cardiol 1995; 75:455-459.
20. Furberg CD, Adams HP, Applegate WB, Byington RB, Espeland MA, Hartwell T, et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation 1994; 90:1679-1687.
21. Baldassare D, Tremoli E, Franceschini G, Michelagnoli S, Sirtori CR. Plasma lipoprotein (a) is an independent factor associated with carotid wall thickening in severely but not moderately hypercholesterolemic patients. Stroke 1996; 27:1044-1049.
22. Hodis HN, Mack WJ, LaBree L, Selzer RH, Liu C-R, Liu C-H, et al. Reduction in carotid arterial wall thickness using lovastatin and dietary therapy. A randomized, controlled clinical trial. Ann Intern Med 1996; 124:548-556.
23. Salonen R, Seppanen K, Rauramaa R, Salonen JT. Prevalence of carotid atherosclerosis and serum cholesterol levels in Eastern Finland. Arteriosclerosis 1988; 8:788-792.
24. Reed DM, Resch JA, Hayashi T, Maclean C, Yano K. A prospective study of cerebral artery atherosclerosis. Stroke 1988; 19:820-825.
25. Heiss G, Sharrett AR, Barnes R, Chambless LE, Szklo M, Alzola C, and the ARIC Investigators. Carotid atherosclerosis measured by B-mode ultrasound in populations; associations with cardiovascular risk factors in the ARIC study. Am J Epidemiol 1991; 134:250-260.
26. Prati P, Vanuzzo D, Casaroli M, Di Chiari A, De Biasi F, Ferguglio GA, et al. Prevalence and determinants of carotid atherosclerosis in a general population. Stroke 1992; 23:1705-1711.
27. Sutton-Tyrrell K, Alcorn HG, Wolfson SK, Kuller LH. Predictors of carotid stenosis in older adults with and without isolated systolic hypertension. Stroke 1993; 24:355-361.
28. Fine-Edelstein JS, Wolf PA, O'Leary DH, Poehlman H, Belanger AJ, Kase CS, et al. Precursors of extracranial carotid atherosclerosis in the Framingham Study. Neurology 1994; 44:1046-1050.
29. Willeit J, Kiechl S, Santer P, Oberhollenzer F, Egger G, Jarosch E, et al. Lipoprotein (a) and asymptomatic carotid artery disease. Evidence of a prominent role in the evolution of advanced carotid plaques: the Bruneck Study. Stroke 1995; 26:1582-1587.
30. Ueshima H, Iida M, Shimamato T, Konishi M, Tsujioka K, Tonigaki M, et al. Multivariate analysis of risk factors for stroke. 8-year follow-up of farming villages in Akita, Japan. Prev Med 1980; 9:722-740.
31. Kagan A, Popper JS, Rhoads GG. Factors related to stroke incidence in Hawaiian Japanese Men. The Honolulu Heart Study. Stroke 1980; 11:14-20.
32. Tanaka H, Hayashi M, Date C, Imai K, Asada M, Shoji H, et al. Epidemiologic studies of stroke in Shibata, a Japanese provincial city: preliminary report on risk factors for cerebral infarction. Stroke 1985; 16:773-780.
33. Salonen JT, Pushka P, Tuomilehto J, Homan K. Relation of blood pressure, serum lipids, and smoking to the risk of cerebral stroke. A longitudinal study in Eastern Finland. Stroke 1982; 13:327-333.
34. Welin L, Svardsudd K, Wilhelmsen L, Larsson B, Tibblin G. Analysis of risk factors for stroke in a cohort of men born in 1913. N Engl J Med 1987; 317:521-526.
35. Iso H, Jacobs DR, Wentworth D, Neaton JD, Cohen JD, for the MRFIT Research Group. Serum cholesterol levels and 6-year mortality from stroke in 350,977 men screened for the Multiple Risk Factor Intervention Trial. N Engl J Med 1989; 320:904-910.
36. Harmsen P, Rosengren A, Tsipogianni A, Wilhelmsen L. Risk factors for middle-aged men in Goteborg, Sweden. Stroke 1990; 21:223-229.
37. Lindenstrom E, Boysen G, Nyboe J. Influence of total cholesterol, high density lipoprotein cholesterol, and triglycerides on risk of cerobrovascular disease: the Copenhagen City Heart Study. BMJ 1994; 309:11-15.
38. Wolf PA, Belanger AJ, D'Agostino RB. Management of risk factors. In: Barnett HJM, Hachinski VC (editors). Cerebrovascular ischemia: treatment and prevention. Neurol Clin 1992; 10:177-191.
39. Tanne D, Yaari S, Goldbourt U. High-density lipoprotein cholesterol and risk of ischemic stroke mortality. A 21-year follow-up of 8,586 men from the Israeli Ischemic Heart Disease Study. Stroke 1997; 28:83-87.
40. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-1389.
41. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335:1001-1009.
42. Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 1997; 278:313-321. An excellent overview of statin agents and their relation to stroke reduction. The authors weigh the risks and benefits of these agents and supply rationale for previous reports of failure for cholesterol lowering in stroke prevention.
43. Blauw GJ, Lagaay AM, Smelt AHM, Westendorp RGJ. Stroke, statins and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. Stroke 1997; 28:946-950. This meta-analysis provides further evidence to support the possible role of lipid control for stroke prevention.
44. Hebert PR, Gaziano JM, Hennekens CH. An overview of trials of cholesterol lowering and risk of stroke. Arch Int Med 1996; 124:914-918.
45. Prospective Studies Collaboration. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Lancet 1995; 346:1647-1653.
46. Espeland MA, Applegate W, Furberg CD, Lefkowitz D, Rice L, Hunninghake D, et al. Estrogen replacement therapy and progression of intimal-medial thickness in the carotid arteries of postmenopausal women. Am J Epidemiol 1995; 142:1011-1019.
47. Bailar JC. The promise and problems of meta-analysis. N Engl J Med 1997; 337:559-560.
48. Gaziano JM, Hebert PR, Hennekens CH. Cholesterol reduction: weighing the benefits and risks. Ann Intern Med 1996; 124:914-918.
49. Summary of the NCEP Adult Treatment Panel II Report. JAMA 1993; 269:3015-3023. The US National Cholesterol Education Panel treatment guidelines for hyperlipidemias.
50. Iribarren C, Jacobs DR, Sadler M, Claxton AJ, Sidney S. Low total serum cholesterol and intracerebral hemorrhagic stroke: is the association confined to elderly men? The Kaiser Permanente Medical Care Program. Stroke 1996; 27:1993-1998.
51. Johannesson M, Jonsson B, Kjekshus J, Olsson AG, Pedersen TR, Wedel H, et al. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl J Med 1997; 336:332-336.